Cosmetic research peptide · Fact sheet
SNAP-8
Also known as Acetyl octapeptide-3
SNAP-8 is a cosmetic name associated with acetyl octapeptide-3. Ingredient identity and manufacturer claims do not establish independent clinical anti-wrinkle efficacy or a safe injectable regimen.
What is SNAP-8?
The NIH substance record identifies acetyl octapeptide-3. SNAP-8 is also a manufacturer trade name for cosmetic ingredients.
Acetyl octapeptide-3 is not acetyl hexapeptide-8 (Argireline); a study of the latter cannot validate SNAP-8.
Benefits & claims
Interest centers on skin or hair appearance. Biological activity does not itself establish a clinical treatment.
What the evidence supports
- A manufacturer product record identifies the cosmetic ingredient family.
- Argireline human studies concern a different peptide and do not establish SNAP-8 benefit.
- There is no verified established therapeutic amount or frequency for SNAP-8 in the reviewed primary sources.
Research areas
- Experimental tissue and cellular responses
- Formulation-specific outcomes
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for SNAP-8. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Acetyl octapeptide-3 is not acetyl hexapeptide-8 (Argireline); a study of the latter cannot validate SNAP-8.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Controlled human clinical outcomes for the exact substance
- Human exposure, pharmacokinetics and repeated-use safety
- Independent replication and formulation equivalence
Side effects & risks
- Cosmetic use does not establish systemic safety, sterility or suitability for injection.
- Independent long-term safety and formulation-specific adverse-event data remain limited.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Limited or unclear evidenceThe reviewed record establishes ingredient identity and cosmetic context. A robust independent human trial of the isolated ingredient was not verified; related-peptide studies are not direct efficacy evidence.
Studies
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
SNAP-8 has no FDA-approved therapeutic product. The cited experiments or cosmetic uses do not establish an approved human treatment.
No FDA-approved product for this entry
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Controlled human clinical outcomes for the exact substance
- Human exposure, pharmacokinetics and repeated-use safety
- Independent replication and formulation equivalence
Summary
There is no verified established therapeutic amount or frequency for SNAP-8 in the reviewed primary sources.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- nihNIH GSRS: acetyl octapeptide-3
Chemical identity record, not approval or clinical efficacy evidence.
- company releaseLubrizol: SNAP-8 peptide solution C
Manufacturer ingredient record; marketing is not independent clinical validation.
- fdaFDA: cosmetics and U.S. law
Cosmetic ingredients generally do not receive FDA premarket approval; disease and structure/function claims can invoke drug regulation.